Regulatory Considerations for Approval of Chimeric Antigen Receptor T Cell Therapies for Treatment of Hematological Malignancies
Mona Elmacken(Center for Biologics Evaluation and Research), Lola A. Fashoyin‐Aje(Center for Drug Evaluation and Research), Upendra Mahat(United States Food and Drug Administration), Nicole Verdun(Center for Biologics Evaluation and Research)
Cited by 2
Related Papers
FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors
|Clinical Cancer Research|2021|567
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19
|New England Journal of Medicine|2021|553
Early safety indicators of COVID-19 convalescent plasma in 5000 patients
|Journal of Clinical Investigation|2020|485
Safety Update
|Mayo Clinic Proceedings|2020|432
Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2024|257